[go: up one dir, main page]

WO2005118541A3 - Heterocyclic compounds and their use as aldosterone synthase inhibitors - Google Patents

Heterocyclic compounds and their use as aldosterone synthase inhibitors Download PDF

Info

Publication number
WO2005118541A3
WO2005118541A3 PCT/EP2005/052418 EP2005052418W WO2005118541A3 WO 2005118541 A3 WO2005118541 A3 WO 2005118541A3 EP 2005052418 W EP2005052418 W EP 2005052418W WO 2005118541 A3 WO2005118541 A3 WO 2005118541A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compounds
synthase inhibitors
aldosterone synthase
compounds
aldosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/052418
Other languages
French (fr)
Other versions
WO2005118541A2 (en
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Christoph Schumacher
Dirk Behnke
Michael Quirmbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Speedel Experimenta AG
Original Assignee
Speedel Experimenta AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT05749325T priority Critical patent/ATE490241T1/en
Priority to JP2007513941A priority patent/JP2008500999A/en
Priority to CA002568164A priority patent/CA2568164A1/en
Priority to BRPI0510412-2A priority patent/BRPI0510412A/en
Priority to EP05749325A priority patent/EP1748986B1/en
Priority to US11/597,615 priority patent/US20080076794A1/en
Application filed by Speedel Experimenta AG filed Critical Speedel Experimenta AG
Priority to DE602005025110T priority patent/DE602005025110D1/en
Publication of WO2005118541A2 publication Critical patent/WO2005118541A2/en
Publication of WO2005118541A3 publication Critical patent/WO2005118541A3/en
Priority to IL179409A priority patent/IL179409A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.
PCT/EP2005/052418 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors Ceased WO2005118541A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2007513941A JP2008500999A (en) 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors
CA002568164A CA2568164A1 (en) 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors
BRPI0510412-2A BRPI0510412A (en) 2004-05-28 2005-05-27 organic compounds
EP05749325A EP1748986B1 (en) 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors
US11/597,615 US20080076794A1 (en) 2004-05-28 2005-05-27 Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
AT05749325T ATE490241T1 (en) 2004-05-28 2005-05-27 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS
DE602005025110T DE602005025110D1 (en) 2004-05-28 2005-05-27 Heterocyclic Compounds And Their Use As Aldosterone Synthesis Inhibitors
IL179409A IL179409A0 (en) 2004-05-28 2006-11-20 Heterocyclic compounds and their use as aldosterone synthase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH0916/04 2004-05-28
CH9162004 2004-05-28
CH11572004 2004-07-09
CH1157/04 2004-07-09

Publications (2)

Publication Number Publication Date
WO2005118541A2 WO2005118541A2 (en) 2005-12-15
WO2005118541A3 true WO2005118541A3 (en) 2006-02-02

Family

ID=34993240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/052418 Ceased WO2005118541A2 (en) 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors

Country Status (11)

Country Link
US (1) US20080076794A1 (en)
EP (1) EP1748986B1 (en)
JP (1) JP2008500999A (en)
AR (1) AR050251A1 (en)
AT (1) ATE490241T1 (en)
BR (1) BRPI0510412A (en)
CA (1) CA2568164A1 (en)
DE (1) DE602005025110D1 (en)
IL (1) IL179409A0 (en)
TW (1) TW200608978A (en)
WO (1) WO2005118541A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076784A1 (en) * 2004-05-28 2008-03-27 Peter Herold Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
AR056888A1 (en) * 2005-12-09 2007-10-31 Speedel Experimenta Ag HIDEROCICLIL IMIDAZOL DERIVATIVES
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
ES2523734T3 (en) 2009-05-28 2014-12-01 Novartis Ag Aminopropionic derivatives substituted as neprilysin inhibitors
JP5466759B2 (en) 2009-05-28 2014-04-09 ノバルティス アーゲー Substituted aminobutyric acid derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
PT2729142T (en) 2011-07-08 2018-10-01 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
MX367525B (en) 2013-02-14 2019-08-26 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors.
BR112016001376A2 (en) 2013-07-25 2017-10-24 Novartis Ag synthetic apelin polypeptide bioconjugates
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CN107406490A (en) 2015-01-23 2017-11-28 诺华股份有限公司 Synthesis APELIN fatty acid conjugates with improved half-life period
JOP20190086A1 (en) 2016-10-21 2019-04-18 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
JP7657151B2 (en) 2018-11-27 2025-04-04 ノバルティス アーゲー Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (en) 2018-11-27 2020-06-30 Novartis Ag CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356673A2 (en) * 1988-09-02 1990-03-07 FARMITALIA CARLO ERBA S.r.l. Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyridines and process for their preparation
EP0366609A2 (en) * 1988-10-26 1990-05-02 Ciba-Geigy Ag Use of bicyclic imidazole derivatives in treating hyperaldosteronism
EP0401707A1 (en) * 1989-06-05 1990-12-12 Daiichi Pharmaceutical Co., Ltd. Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity
EP0426225A2 (en) * 1989-11-01 1991-05-08 Janssen Pharmaceutica N.V. (6,7-dihydro-5H-pyrrolo[1,2-c]-imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
WO1993015079A1 (en) * 1992-01-27 1993-08-05 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd New bicyclic condensed imidazole derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859691A (en) * 1987-07-08 1989-08-22 Ciba-Geigy Corporation Certain 1,2-benzisoxazole derivatives
JP3170273B2 (en) * 1989-06-05 2001-05-28 第一製薬株式会社 Condensed triazine derivatives and their intermediates
JP2004536082A (en) * 1999-10-22 2004-12-02 グラクソ グループ リミテッド In vivo imaging
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356673A2 (en) * 1988-09-02 1990-03-07 FARMITALIA CARLO ERBA S.r.l. Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyridines and process for their preparation
EP0366609A2 (en) * 1988-10-26 1990-05-02 Ciba-Geigy Ag Use of bicyclic imidazole derivatives in treating hyperaldosteronism
EP0401707A1 (en) * 1989-06-05 1990-12-12 Daiichi Pharmaceutical Co., Ltd. Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity
EP0426225A2 (en) * 1989-11-01 1991-05-08 Janssen Pharmaceutica N.V. (6,7-dihydro-5H-pyrrolo[1,2-c]-imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
WO1993015079A1 (en) * 1992-01-27 1993-08-05 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd New bicyclic condensed imidazole derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 07 31 July 1997 (1997-07-31) *

Also Published As

Publication number Publication date
TW200608978A (en) 2006-03-16
JP2008500999A (en) 2008-01-17
DE602005025110D1 (en) 2011-01-13
EP1748986A2 (en) 2007-02-07
AR050251A1 (en) 2006-10-11
CA2568164A1 (en) 2005-12-15
IL179409A0 (en) 2007-05-15
BRPI0510412A (en) 2007-10-23
EP1748986B1 (en) 2010-12-01
ATE490241T1 (en) 2010-12-15
US20080076794A1 (en) 2008-03-27
WO2005118541A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005118557A3 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2005118541A3 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
TW200616623A (en) Organic compounds
WO2006005726A3 (en) Heterocyclic compounds
TW200716636A (en) Heterocyclic spiro-compounds
WO2006128852A3 (en) Heterocyclic spiro-compounds as aldosterone synthase inhibitors
WO2006005741A3 (en) Piperdine derivatives as renin inhibitors
MX2009008264A (en) Heterocyclic spiro-compounds.
TW200716105A (en) Imidazole compounds
WO2008012532A3 (en) : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
WO2007065942A3 (en) Bis-heterocyclic imidazolyl compounds
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
WO2010003475A8 (en) Novel pyrrolidone derivatives for use as metap-2 inhibitors
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
WO2008053194A3 (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
WO2007015017A3 (en) Novel polyquinoline derivatives and the therapeutic use thereof
WO2008079814A3 (en) Mapk/erk kinase inhibitors
TW200745084A (en) Novel compounds
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2008046919A3 (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2008074752A3 (en) Indolylmaleimide derivatives as kinase inhibitors
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2008054956A3 (en) Kinase inhibitors
WO2006103277A3 (en) 2 , 4 , 5-substituted piperidines as renin inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 179409

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2568164

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11597615

Country of ref document: US

Ref document number: 2005749325

Country of ref document: EP

Ref document number: 7100/DELNP/2006

Country of ref document: IN

Ref document number: 200580016957.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007513941

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2005749325

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0510412

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11597615

Country of ref document: US